IBDEI0R8 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12476,1,3,0)
 ;;=3^Hyperlipidemia,Other
 ;;^UTILITY(U,$J,358.3,12476,1,4,0)
 ;;=4^E78.4
 ;;^UTILITY(U,$J,358.3,12476,2)
 ;;=^5002968
 ;;^UTILITY(U,$J,358.3,12477,0)
 ;;=E78.5^^74^722^43
 ;;^UTILITY(U,$J,358.3,12477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12477,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,12477,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,12477,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,12478,0)
 ;;=D35.2^^74^722^6
 ;;^UTILITY(U,$J,358.3,12478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12478,1,3,0)
 ;;=3^Benign Neop Pituitary Gland
 ;;^UTILITY(U,$J,358.3,12478,1,4,0)
 ;;=4^D35.2
 ;;^UTILITY(U,$J,358.3,12478,2)
 ;;=^5002145
 ;;^UTILITY(U,$J,358.3,12479,0)
 ;;=D35.3^^74^722^4
 ;;^UTILITY(U,$J,358.3,12479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12479,1,3,0)
 ;;=3^Benign Neop Craniopharyngeal Duct
 ;;^UTILITY(U,$J,358.3,12479,1,4,0)
 ;;=4^D35.3
 ;;^UTILITY(U,$J,358.3,12479,2)
 ;;=^5002146
 ;;^UTILITY(U,$J,358.3,12480,0)
 ;;=E21.0^^74^722^44
 ;;^UTILITY(U,$J,358.3,12480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12480,1,3,0)
 ;;=3^Hyperparathyroidism,Primary
 ;;^UTILITY(U,$J,358.3,12480,1,4,0)
 ;;=4^E21.0
 ;;^UTILITY(U,$J,358.3,12480,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,12481,0)
 ;;=I10.^^74^722^46
 ;;^UTILITY(U,$J,358.3,12481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12481,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,12481,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,12481,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,12482,0)
 ;;=E83.52^^74^722^41
 ;;^UTILITY(U,$J,358.3,12482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12482,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,12482,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,12482,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,12483,0)
 ;;=E23.0^^74^722^50
 ;;^UTILITY(U,$J,358.3,12483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12483,1,3,0)
 ;;=3^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,12483,1,4,0)
 ;;=4^E23.0
 ;;^UTILITY(U,$J,358.3,12483,2)
 ;;=^60685
 ;;^UTILITY(U,$J,358.3,12484,0)
 ;;=D35.01^^74^722^7
 ;;^UTILITY(U,$J,358.3,12484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12484,1,3,0)
 ;;=3^Benign Neop Right Adrenal Gland
 ;;^UTILITY(U,$J,358.3,12484,1,4,0)
 ;;=4^D35.01
 ;;^UTILITY(U,$J,358.3,12484,2)
 ;;=^5002143
 ;;^UTILITY(U,$J,358.3,12485,0)
 ;;=D35.02^^74^722^5
 ;;^UTILITY(U,$J,358.3,12485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12485,1,3,0)
 ;;=3^Benign Neop Left Adrenal Gland
 ;;^UTILITY(U,$J,358.3,12485,1,4,0)
 ;;=4^D35.02
 ;;^UTILITY(U,$J,358.3,12485,2)
 ;;=^5002144
 ;;^UTILITY(U,$J,358.3,12486,0)
 ;;=E55.9^^74^722^79
 ;;^UTILITY(U,$J,358.3,12486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12486,1,3,0)
 ;;=3^Vitamin D Deficiency,Unspec
 ;;^UTILITY(U,$J,358.3,12486,1,4,0)
 ;;=4^E55.9
 ;;^UTILITY(U,$J,358.3,12486,2)
 ;;=^5002799
 ;;^UTILITY(U,$J,358.3,12487,0)
 ;;=E26.9^^74^722^40
 ;;^UTILITY(U,$J,358.3,12487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12487,1,3,0)
 ;;=3^Hyperaldosteronism,Unspec
 ;;^UTILITY(U,$J,358.3,12487,1,4,0)
 ;;=4^E26.9
 ;;^UTILITY(U,$J,358.3,12487,2)
 ;;=^5002738
 ;;^UTILITY(U,$J,358.3,12488,0)
 ;;=E27.49^^74^722^2
 ;;^UTILITY(U,$J,358.3,12488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12488,1,3,0)
 ;;=3^Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,12488,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,12488,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,12489,0)
 ;;=E16.2^^74^722^48
 ;;^UTILITY(U,$J,358.3,12489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12489,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,12489,1,4,0)
 ;;=4^E16.2
